Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BETRF OTCMKTS:ICOTF NASDAQ:TLGT OTCMKTS:TOWTF OTCMKTS:TRLPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.06+5.3%$0.07$0.05▼$0.15$8.30M1.4512,219 shs23,728 shsICOTFiCo Therapeutics$0.47-0.2%$0.37$0.80▼$1.82$4.25M2.034,760 shs53,408 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsTOWTFTower One Wirls$0.00$0.00▼$0.00$12KN/AN/AN/ATRLPFAcerus Pharmaceuticals$0.22$0.22$0.08▼$0.34$56.90M2.65,474 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma+5.25%+1.10%-1.23%+16.55%-51.51%ICOTFiCo Therapeutics-0.12%-4.08%+14.38%+2.17%+24.87%TLGTTeligent0.00%0.00%0.00%0.00%0.00%TOWTFTower One Wirls0.00%0.00%0.00%0.00%0.00%TRLPFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBETRFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/ATOWTFTower One WirlsN/AN/AN/AN/AN/AN/AN/AN/ATRLPFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife Pharma 0.00N/AN/AN/AICOTFiCo Therapeutics 0.00N/AN/AN/ATLGTTeligent 0.00N/AN/AN/ATOWTFTower One Wirls 0.00N/AN/AN/ATRLPFAcerus Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.04) per shareN/AICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/ATOWTFTower One WirlsN/AN/AN/AN/AN/AN/ATRLPFAcerus Pharmaceuticals$7.38M7.71N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$2.55M-$0.01N/A∞N/AN/AN/A-609.07%9/23/2025 (Estimated)ICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ATOWTFTower One WirlsN/AN/A0.00N/AN/AN/AN/AN/AN/ATRLPFAcerus Pharmaceuticals-$18.79M-$0.08N/A∞N/A-254.66%-346.72%-94.54%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ATOWTFTower One WirlsN/AN/AN/AN/AN/ATRLPFAcerus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.040.04ICOTFiCo TherapeuticsN/A0.720.72TLGTTeligentN/AN/AN/ATOWTFTower One WirlsN/AN/AN/ATRLPFAcerus Pharmaceuticals0.641.350.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%ICOTFiCo TherapeuticsN/ATLGTTeligentN/ATOWTFTower One WirlsN/ATRLPFAcerus Pharmaceuticals0.02%Insider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%ICOTFiCo TherapeuticsN/ATLGTTeligent0.17%TOWTFTower One Wirls31.97%TRLPFAcerus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableTLGTTeligent2,357N/AN/AOptionableTOWTFTower One WirlsN/AN/AN/ANot OptionableTRLPFAcerus Pharmaceuticals29258.62 millionN/ANot OptionableBETRF, TLGT, TOWTF, ICOTF, and TRLPF HeadlinesRecent News About These CompaniesTakeda Pharmaceutical Co. Ltd. ADRFebruary 8, 2024 | wsj.comOther OTC Pharmaceuticals - LithuaniaSeptember 17, 2023 | statista.comS2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitJanuary 1, 2023 | seekingalpha.comAcerus Reports Second Quarter 2022 Financial ResultsAugust 9, 2022 | financialpost.comFAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | financialpost.comFMedia Sentiment Over TimeBETRF, TLGT, TOWTF, ICOTF, and TRLPF Company DescriptionsBetterLife Pharma OTCMKTS:BETRF$0.06 +0.00 (+5.25%) As of 07/8/2025 02:34 PM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Teligent NASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.Tower One Wirls OTCMKTS:TOWTFTower One Wireless Corp. owns, develops, and operates build-to-suit multitenant communications towers in Argentina, Colombia, Mexico, the United States, and internationally. It primarily engages in the leasing of space on communications sites to mobile network operators. The company also provides tower-related services, including site acquisition, zoning and permitting, structural analysis, and construction. Tower One Wireless Corp. was incorporated in 2005 and is headquartered in Bogotá, Colombia.Acerus Pharmaceuticals OTCMKTS:TRLPF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
